Categories
Change Password!
Reset Password!
Merimepodib
oral may be the new hope for the treatment of coronavirus.
After the authorization
of an Investigational New Drug Application by the FDA as announced on 18 May,
2020, the new pharmaceutical subsidiary has declared that a randomized, double-blind phase 2 study will be started
assessing merimepodib oral solution for coronavirus disease 2019 (COVID-19)
treatment.
Merimepodib
is an antiviral drug with proven efficacy in preclinical study against severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Merimepodib when used
alone or along with remdesivir, was linked with a substantial decrease in viral
production in cell cultures as per the results of a study anticipating
peer review.
The phase 2
study will compare the safety and efficacy of merimepodib to placebo in
hospitalized adult, COVID-19 patients who are either on non-invasive
ventilation/high flow oxygen devices or are in need of additional oxygen. As
expected, this study will be performed at various sites in the US.
BioSig
Antiviral Merimepodib to Be Investigated in Phase 2 Trial for COVID-19
Comments (0)